LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Amgen Inc

Închisă

SectorSănătate

277.02 -0.75

Rezumat

Modificarea prețului

24h

Curent

Minim

275.38

Maxim

281.19

Indicatori cheie

By Trading Economics

Venit

1.1B

1.7B

Vânzări

-937M

8.1B

P/E

Medie Sector

26.375

50.291

EPS

4.9

Randament dividend

3.29

Marjă de profit

21.23

Angajați

28,000

EBITDA

-1.7B

1.2B

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+17.07% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

3.29%

2.40%

Următoarele câștiguri

5 aug. 2025

Data viitoare de dividende

5 sept. 2025

Următoarea dată ex-dividende

15 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-2.5B

156B

Deschiderea anterioară

277.77

Închiderea anterioară

277.02

Sentimentul știrilor

By Acuity

39%

61%

121 / 380 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Amgen Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

23 iun. 2025, 19:24 UTC

Principalele dinamici ale pieței

Amgen Expands MariTide Development Plans After Weight-Loss Trial -- Update

23 iun. 2025, 19:07 UTC

Principalele dinamici ale pieței

Amgen Expands MariTide Development Plans After Successful Weight-Loss Trial

1 mai 2025, 20:17 UTC

Câștiguri

Amgen 1Q Revenue Up 9% as Many Products Deliver Double-Digit Sales Growth

28 mai 2025, 18:09 UTC

Câștiguri

Heart Disease Could Be a Goner When These New -2-

28 mai 2025, 18:09 UTC

Câștiguri

Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com

19 mai 2025, 16:13 UTC

Achiziții, Fuziuni, Preluări

Regeneron Is Buying 23andMe. The Deal Is a Head Scratcher. -- Barrons.com

1 mai 2025, 20:01 UTC

Câștiguri

Amgen: FY25 Share Repurchases Not to Exceed $500M

1 mai 2025, 20:01 UTC

Câștiguri

Amgen: Guidance Includes Estimated Impact of Implemented Tariffs>AMGN

1 mai 2025, 20:01 UTC

Câștiguri

Amgen Sees FY25 Capital Expenditures About $2.3B

1 mai 2025, 20:01 UTC

Câștiguri

Amgen: Guidance Doesn't Account for Any Tariffs That Could Be Implemented in Future, Including Sector-specific Tariffs

1 mai 2025, 20:01 UTC

Câștiguri

Amgen 1Q Repatha Sales $656M >AMGN

1 mai 2025, 20:01 UTC

Câștiguri

Amgen 1Q EVENITY Sales $442M >AMGN

1 mai 2025, 20:01 UTC

Câștiguri

Amgen 1Q Worldwide Neulasta Sales $129M >AMGN

1 mai 2025, 20:01 UTC

Câștiguri

Amgen Sees FY25 Adj EPS $20-Adj EPS $21.20 >AMGN

1 mai 2025, 20:01 UTC

Câștiguri

Amgen 1Q Net $1.73B >AMGN

1 mai 2025, 20:01 UTC

Câștiguri

Amgen Sees FY25 EPS $12.21-EPS $13.46 >AMGN

1 mai 2025, 20:01 UTC

Câștiguri

Amgen 1Q Adj EPS $4.90 >AMGN

1 mai 2025, 20:01 UTC

Câștiguri

Amgen Sees FY25 Rev $34.3B-$35.7B >AMGN

1 mai 2025, 20:01 UTC

Câștiguri

Amgen 1Q Worldwide XGEVA Sales $566M >AMGN

1 mai 2025, 20:01 UTC

Câștiguri

Amgen 1Q Worldwide Prolia Sales $1.1B >AMGN

1 mai 2025, 20:01 UTC

Câștiguri

Amgen 1Q EPS $3.20 >AMGN

1 mai 2025, 20:01 UTC

Câștiguri

Amgen 1Q Worldwide Enbrel Sales $510M >AMGN

1 mai 2025, 20:01 UTC

Câștiguri

Amgen 1Q Rev $8.15B >AMGN

1 mai 2025, 20:01 UTC

Câștiguri

Amgen 1Q Worldwide Enbrel Sales $510M >AMGN

1 mai 2025, 20:01 UTC

Câștiguri

Amgen 1Q Rev $8.1B >AMGN

1 mai 2025, 20:01 UTC

Câștiguri

Amgen 1Q Net $1.73B >AMGN

1 mai 2025, 20:01 UTC

Câștiguri

Amgen 1Q Worldwide Neulasta Sales $129M >AMGN

1 mai 2025, 20:01 UTC

Câștiguri

Amgen Sees FY EPS $12.21-EPS $13.46 >AMGN

1 mai 2025, 20:01 UTC

Câștiguri

Amgen 1Q Worldwide Prolia Sales $1.1B >AMGN

1 mai 2025, 20:01 UTC

Câștiguri

Amgen 1Q Worldwide XGEVA Sales $566M >AMGN

Comparație

Modificare preț

Amgen Inc Așteptări

Obiectiv de preț

By TipRanks

17.07% sus

Prognoză pe 12 luni

Medie 326.76 USD  17.07%

Maxim 400 USD

Minim 252 USD

În baza a 22 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAmgen Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

22 ratings

11

Cumpărare

10

Păstrare

1

Vânzare

Scor tehnic

By Trading Central

270.44 / 276.44Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Strong Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

121 / 380 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.